Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Cytokine Release Syndrome

• Adjunctive Methylene Blue for Immunotherapy-related CRS and ICANS: Phase I Study
• Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial)
• A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma
• Pre-emptive Anakinra for Cytokine Event Reduction
• Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm for the Treatment of Acute Respiratory Distress Syndrome (ARDS) Caused by SARS-Cov-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV
• Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab
• Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma
• Esmolol in Sepsis Management:Evaluating Immunomodulatory Effects and Impact on Patient Outcomes
• Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM
• MRG-001 as an Immunoregulatory and Regenerative Therapy for ARDS Patients
• Ruxolitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
• Study of CTO1681 for the Prevention and Treatment of CRS in DLBCL Patients Receiving CAR T-Cell Therapy
• Anakinra in Dengue With Hyperinflammation ( AnaDen )
• Cytokine Guided Risk Stratification and Treatment in Pediatric Hemophagocytic Lymphohistiocytosis
• Jafron Haemoadsorption During Cardiopulmonary Bypass
• Tadekinig Alfa (IL-18BP) Rescue Therapy for CAR T Cell Related Cytokine Release Syndrome (CRS) and HLH-like Syndrome
• High-Dose Corticosteroid or Tocilizumab for Clinical Worsening of COVID-19
• PROlectin M, a Nucleocapsid TErminal GaleCTin Antagonist for COVID-19
• Tazemetostat for the Treatment of Moderate to Severe COVID-19 Infection
• Exploratory Regimen of Basiliximab for Treatment of Pulmonary Cytokine Storm in SARS-CoV-2 Hospitalized Adult Patients
• Safety and Effectiveness of Cyclosporin in the Management of COVID19 ARDS Patients in Alexandria University Hospital
• Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy
• Inflammatory Response to Opioid Versus Opioid Free Anesthesia
• The Impact of Fecal Microbiota Transplantation as an Immunomodulation on the Risk Reduction of COVID-19 Disease Progression With Escalating Cytokine Storm and Inflammatory Parameters
• Cyclosporine on Day Zero as Prophylaxis for Cytokine Release Syndrome
• Treatment of Severe COVID-19 Patients Using Secretome of Hypoxia-Mesenchymal Stem Cells in Indonesia
• TOCILIZUMAB - An Option for Patients With COVID-19 Associated Cytokine Release Syndrome; A Single Center Experience
• Management of Cytokine Storms in Severe COVID-19 Patients With Autologous Activated Platelet-rich Plasma Therapy
• Sarilumab Treatment In cytoKinE Storm Caused by Infection With COVID-19
• Anakinra in the Management of COVID-19 Infection
• Anakinra, COVID-19, Cytokine Storm
• Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome
• Intramuscular Effect of Polymerized Type I Collagen on the Cytokine Storm in COVID-19 Patients
• Investigational Treatments for COVID-19 in Tertiary Care Hospital of Pakistan
• Efficacy and Safety of Itolizumab in COVID-19 Complications
• To Determine the Efficacy of Neurokinin 1 Receptor Antagonist as a Therapeutic Tool Against Cytokine Storm and Respiratory Failure in Covid-19 Patients
• Clinical Trial of the Use of Anakinra in Cytokine Storm Syndrome Secondary to Covid-19 (ANA-COVID-GEAS)
• Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).
• RepurpoSing Old Drugs TO SuppRess a Modern Threat: COVID-19 STORM
• A Phase 2 Study to Evaluate Axatilimab for Hospitalized Patients With Respiratory Involvement Secondary to COVID-19
• Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers
• Ultra Low Doses of Therapy With Radiation Applicated to COVID-19
• CORONA: A Study Using DeltaRex-G Gene Therapy for Symptomatic COVID-19
• Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19
• Fluoxetine to Reduce Intubation and Death After COVID19 Infection
• Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS
• Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome
• Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia
• Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm
• Early Treatment of Cytokine Storm Syndrome in Covid-19
• Prophylactic Corticosteroid to Prevent COVID-19 Cytokine Storm
• Defibrotide as Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome of Covid 19.
• Treatment of COVID-19 Patients With Anti-interleukin Drugs
• Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19
• A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity
• Metoprolol for the Treatment of Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells
• A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy
• Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
• Tocilizumab for Cytokine Release Syndrome Prophylaxis in Haploidentical Transplantation
• Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome
• Tocilizumab and Hemophagocytic Lymphohistiocytosis (HLH)